abbv-0805
mAbexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 31, 2019 (NCT04127695)
Timeline
Indications
Mechanism of action
- Alpha-synucleinINHIBITOR
SNCA inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06671938 | Phase 2 | Nov 22, 2024 | BioArctic AB, Worldwide Clinical Trials |
| NCT04127695 | Phase 1 | Oct 31, 2019 | AbbVie |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbbVie | For profit | 1 | 1 | 1 | 2019 |
| BioArctic AB | For profit | 1 | 1 | 1 | 2024 |
| Worldwide Clinical Trials | For profit | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1